LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
DexCom
DXCM
Collegium Pharmaceutical
COLL
Halozyme Therapeutics
HALO
Constellation Brands
STZ
(Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating cash flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -104.76%-14M | -34.62%85M | 1,189.47%245M | -65.27%423M | -111.30%-20M | -15.76%294M | -61.08%130M | -94.69%19M | 129.81%1.22B | 21.23%177M |
Net income from continuing operations | -24.14%110M | -13.38%123M | -17.01%122M | 10.48%485M | -63.31%51M | 5.07%145M | 30.28%142M | 177.36%147M | 8.40%439M | 40.40%139M |
Operating gains losses | 75.00%-1M | ---6M | -200.00%-3M | 263.16%62M | 800.00%63M | -500.00%-4M | --0 | 120.00%3M | 28.30%-38M | 35.71%-9M |
Depreciation and amortization | -10.53%17M | -14.29%18M | -33.33%14M | 6.85%78M | -10.53%17M | 0.00%19M | 5.00%21M | 40.00%21M | 630.00%73M | 72.73%19M |
Deferred tax | -83.33%1M | 120.00%1M | 650.00%15M | -154.55%-6M | -550.00%-9M | 500.00%6M | -266.67%-5M | -60.00%2M | -26.67%11M | -71.43%2M |
Other non cashItems | -251.24%-183M | -33.93%-75M | 163.47%106M | -138.07%-265M | -2,816.67%-163M | -37.31%121M | -126.17%-56M | -159.01%-167M | 404.35%696M | -86.36%6M |
Change in working capital | 205.56%19M | -55.56%4M | -2,200.00%-23M | 88.89%-3M | 187.50%7M | -20.00%-18M | 400.00%9M | 0.00%-1M | -292.86%-27M | -900.00%-8M |
-Change in receivables | 152.38%11M | 71.43%-2M | -275.00%-15M | 19.05%-34M | 91.30%-2M | -40.00%-21M | -16.67%-7M | -300.00%-4M | -400.00%-42M | ---23M |
-Change in payables and accrued expense | -120.00%-1M | -52.63%9M | -200.00%-5M | 80.95%38M | -47.06%9M | 66.67%5M | 533.33%19M | 350.00%5M | 800.00%21M | 750.00%17M |
-Change in other working capital | 550.00%9M | 0.00%-3M | -50.00%-3M | -16.67%-7M | --0 | 33.33%-2M | ---3M | -100.00%-2M | -300.00%-6M | -100.00%-2M |
Cash from discontinued operating activities | ||||||||||
Operating cash flow | -104.76%-14M | -34.62%85M | 1,189.47%245M | -65.27%423M | -111.30%-20M | -15.76%294M | -61.08%130M | -94.69%19M | 129.81%1.22B | 21.23%177M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 104.02%31M | -110.69%-1.34B | 123.97%76M | 25.99%-2.26B | 16.36%-537M | 6.55%-771M | 61.27%-636M | -687.04%-317M | -1,896.73%-3.06B | 17.37%-642M |
Net investment purchase and sale | -38.46%40M | -298.53%-135M | -74.05%34M | 184.86%269M | -93.83%5M | 208.33%65M | 116.27%68M | 63.75%131M | 51.45%-317M | 115.58%81M |
Net proceeds payment for loan | 102.79%23M | -73.56%-1.18B | 117.11%71M | 13.74%-2.44B | 35.90%-525M | -11.94%-825M | 43.63%-677M | -460.81%-415M | -607.35%-2.83B | -238.43%-819M |
Net PPE purchase and sale | -190.91%-32M | -11.11%-30M | 12.12%-29M | 7.37%-88M | 0.00%-17M | 60.71%-11M | -17.39%-27M | -22.22%-33M | -63.79%-95M | -13.33%-17M |
Net business purchase and sale | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --188M | --113M |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 104.02%31M | -110.69%-1.34B | 123.97%76M | 25.99%-2.26B | 16.36%-537M | 6.55%-771M | 61.27%-636M | -687.04%-317M | -1,896.73%-3.06B | 17.37%-642M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -55.85%181M | 238.40%1.65B | -218.16%-410M | 9,566.67%1.74B | 462.04%496M | -43.29%410M | 193.65%487M | 822.92%347M | -98.96%18M | -1,078.57%-137M |
Increase decrease in deposit | 124.94%1.78B | 170.49%258M | 103.96%23M | -124.03%-62M | 220.25%95M | 91.28%790M | 13.48%-366M | -267.44%-581M | -90.09%258M | -128.01%-79M |
Net issuance payments of debt | -360.36%-1.56B | 55.24%1.44B | -128.72%-282M | 7,037.93%2.01B | 2,561.11%443M | -196.02%-338M | 2,742.86%925M | 399.39%982M | 95.74%-29M | 92.21%-18M |
Net commonstock issuance | --0 | 88.00%-3M | --0 | 16.28%-36M | --1M | --0 | -92.31%-25M | 60.00%-12M | 0.00%-43M | --0 |
Net preferred stock issuance | --0 | --0 | ---111M | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
Cash dividends paid | 2.22%-44M | 4.44%-43M | 0.00%-46M | -1.68%-182M | -4.55%-46M | 0.00%-45M | 0.00%-45M | -2.22%-46M | -9.15%-179M | -7.32%-44M |
Net other financing activities | 33.33%4M | --0 | 50.00%6M | -27.27%8M | -25.00%3M | 0.00%3M | 50.00%-2M | -50.00%4M | -31.25%11M | 0.00%4M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -55.85%181M | 238.40%1.65B | -218.16%-410M | 9,566.67%1.74B | 462.04%496M | -43.29%410M | 193.65%487M | 822.92%347M | -98.96%18M | -1,078.57%-137M |
Net cash flow | ||||||||||
Beginning cash position | 10.33%1.88B | -13.70%1.49B | -5.85%1.58B | -52.08%1.67B | -28.08%1.64B | -16.02%1.7B | -55.33%1.72B | -52.08%1.67B | 152.57%3.49B | -44.62%2.28B |
Current changes in cash | 395.52%198M | 2,168.42%393M | -281.63%-89M | 94.61%-98M | 89.87%-61M | -127.13%-67M | 98.96%-19M | -86.54%49M | -186.21%-1.82B | 2.43%-602M |
End cash position | 26.94%2.08B | 10.33%1.88B | -13.70%1.49B | -5.85%1.58B | -5.85%1.58B | -28.08%1.64B | -16.02%1.7B | -55.33%1.72B | -52.08%1.67B | -52.08%1.67B |
Free cash flow | -116.25%-46M | -46.60%55M | 1,642.86%216M | -70.17%335M | -123.13%-37M | -11.84%283M | -66.88%103M | -104.23%-14M | 137.92%1.12B | 22.14%160M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |